Vice President Real-World Data & Innovation
CurrentProduct Innovation: Responsible for ideation, market research, business development, technical partnerships, and go-to-market strategy for an on-platform data science environment to aid in healthcare research and patient trial identification. The product, called Lucid, was released in October 2022 and many pharmaceutical companies and academic health centers have subscribed to the platform. The Lucid platform is expanding to support federated analytics to unlock ex-US data.Product Enablement: Responsible for the optimization of engineering teams through the development and adoption of data quality, cataloging, and operations oversight.Curated Data: Established data science and engineering team to develop therapeutic-specific datasets for research customers. Current areas of focus include Multiple Myeloma, Melanoma, Hypertrophic Cardiomyopathy, and inflammatory bowel disease. Each dataset includes EMR and claims-related information along with progress and risk scores.Special Projects: Identifying and developing new technologies and techniques to take advantage of emerging market opportunities. Projects include synthetic clinical data, tumor image detection, and improved NLP performance.